All Open Clinical Trials
Below is a list of all open NCI Center for Cancer Research (CCR) clinical trials, including studies that are currently recruiting patients (i.e. Open - Recruiting) as well as trials that will be recruiting soon (i.e., Open - Not yet Recruiting). Most recently opened trials are listed first.
All CCR clinical trials take place at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.
Clinical trials at the NIH Clinical Center are open to patients with cancer, HIV, or immunodeficiency disorders, regardless of where they live in the United States.
-
Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients with Advanced Cancer
Open - Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-20-C-0001Investigator Marijo Bilusic, M.D., Ph.D. -
A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Open - RecruitingNCI Protocol ID NCI-19-C-0143Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0138Investigator Frank I. Lin, M.D. -
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0136Investigator Steven Z. Pavletic, M.D., M.S.Share this trial: Referral ContactsContact Name Phone Number -
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Open - RecruitingNCI Protocol ID NCI-19-C-0137Investigator Andrea B. Apolo, M.D.Share this trial: Referral ContactsContact Name Phone Number -
Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Open - RecruitingNCI Protocol ID NCI-19-C-0135Investigator Naris Nilubol, M.D., F.A.C.S. -
A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses with Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0134Investigator Ronald E. Gress, M.D. -
Natural history and evaluation of abnormal and nonreportable noninvasive prenatal testing NIPT results and its association with maternal neoplasia
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0132Investigator Christina M. Annunziata, M.D., Ph.D. -
Development and Psychometric Testing of a Pediatric Chronic Graft- Versus-Host Disease (GVHD) Symptom Scale (PCSS)
Open - RecruitingNCI Protocol ID NCI-19-C-0131Investigator Lori Wiener, Ph.D., DCSW, LCSW-C -
Development and Psychometric Testing of a Pediatric Chronic GVHD Symptom Scale (PCSS)
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-19-C-0121Investigator Lori Wiener, Ph.D., DCSW, LCSW-C -
A Phase II study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0130Investigator Christian S. Hinrichs, M.D. -
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal Carcinomatosis
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0129Investigator Jeremy L. Davis, M.D. -
A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid Tumors
Open - RecruitingNCI Protocol ID NCI-19-C-0128Investigator Christine Campo Alewine, M.D., Ph.D. -
A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults with Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Open - RecruitingNCI Protocol ID NCI-19-C-0127Investigator Azam Ghafoor, M.D.Share this trial: Referral ContactsContact Name Phone Number -
Phase II Study of Oral Vancomycin in Patients with Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC)
Open - RecruitingNCI Protocol ID NCI-19-C-0125Investigator Tim F. Greten, M.D. -
An Open-Label, Multicenter Rollover Study to Provide Continued Treatment with Anetumab Ravtansine For Participants with Solid Tumors Who Were Enrolled in Previous Bayer-Sponsored Studies.
Open - RecruitingNCI Protocol ID NCI-19-C-0119Investigator Raffit Hassan, M.D. -
A Phase 1 / 2 Single Arm Open-label Clinical Trial of TC-210 T-Cells in Patients with Advanced Mesothelin Expressing Cancer
Open - RecruitingNCI Protocol ID NCI-19-C-0117Investigator Raffit Hassan, M.D. -
A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma
Open - RecruitingNCI Protocol ID NCI-19-C-0116Investigator Mark Roschewski, M.D. -
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Open - RecruitingNCI Protocol ID NCI-19-C-0112Investigator Christopher G. Kanakry, M.D. -
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Open - RecruitingNCI Protocol ID NCI-19-C-0104Investigator William L. Dahut, M.D.